Click on the article title to read more.

Background: Cutaneous melanoma is the leading cause of skin cancer-related mortality, and early detection is crucial to improving prognosis. Teledermatology (TD) has increasingly been adopted in melanoma care to address growing demand and limited access to specialists. This systematic review aimed to evaluate the role of TD in the diagnosis and management of suspected melanoma under real-world clinical conditions. Methods: The review was conducted and reported in accordance with the PRISMA 2020 guidelines. Literature searches were performed in PubMed, Embase, Web of Science, and Scopus up to December 2024. Studies assessing TD use in routine practice were included, focusing on diagnostic accuracy, prognostic indicators, waiting times, satisfaction, and economic outcomes. Results: TD showed high sensitivity and specificity, particularly when dermoscopic images and expert interpretation were available. Some studies reported reduced Breslow thickness and shorter delays compared to face-to-face care. Overall satisfaction was high among both patients and clinicians. Economic evaluations suggested potential cost savings, although formal analyses were limited. The use of artificial intelligence tools yielded mixed results and was generally perceived with caution in the absence of clinical supervision. Conclusions: Teledermatology appears to be a useful approach for improving access and supporting early diagnosis in melanoma care. Its effectiveness depends on proper implementation and integration into clinical workflows.

Recurrent granulomatous rosacea in a paediatric patient prompted an investigation that unveiled a rare gain-of-function mutation in the STAT1 gene. This case highlights the clinical diversity associated with STAT1 mutations and underscores the importance of considering genetic factors in unexplained immunodeficiency and skin conditions, offering valuable insights for diagnosis and treatment.

Breast cancer, the most common malignancy in women, often involves overexpression of human epidermal growth factor receptor 2 (HER2), indicating poor prognosis. Trastuzumab emtansine (T-DM1) is an effective therapeutic option. Although it does have side-effects, these rarely include skin-related issues. However, we present here a case report of a patient with HER2-positive breast carcinoma who, while undergoing T-DM1 treatment, manifested eruptive telangiectatic macules, a rarely reported adverse effect. We conducted a literature review and identified some reports of cases where cutaneous side-effects of T-DM1 were associated with hepatic abnormalities, indicating potential systemic implications. Monitoring for liver damage, possibly through hepatic elastography, could aid in managing T-DM1-associated complications.